About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
The Union League of Philadelphia 140 South Broad Street Philadelphia, PA 19102 Tel: (215) 405-9578 www.unionleague.org/
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- Tracon raises $27M in B roundTracon Pharmaceuticals Inc. (San Diego, Calif.) raised $27 million in a series B round led by New Enterprise Associates. Additional new investors included BioMed Ventures and an undisclosed institutional investor. Existing investors JAFCO; Nextech Invest; Brookline Investments; Arcus Ventures; and BHP also participated.
Tracon is developing TRC105, a human chimeric mAb against endoglin (CD105; ENG). The compound is in multiple oncology trials, including Phase II trials to treat renal cell carcinoma and glioblastoma and Phase I/II trials to treat metastatic breast cancer and soft tissue sarcoma.
Paul Walker of New Enterprise Associates will join the Tracon board and Bruce Steel of BioMed Ventures will join as a board observer. Tracon also hired Patricia Bitar as CFO. Bitar was VP and corporate controller at NuVasive Inc. (NASDAQ:NUVA).
Industry News from PharmAsia
- Regulation, Reimbursement Notes From TurkeyA PharmAsia News update shows Turkey working on support policies for domestic medical devices and pharmaceutical R&D, as well as more enforcement action related to fake cancer drugs.
Upcoming Supporter Events
Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel